0
0
0
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
12/15/2023, 3:51 PM
Summary of Bill HRES 309
Bill 118 HRES 309, titled "Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care," is a resolution that was introduced in the US Congress. The purpose of this resolution is to affirm the belief that the Food and Drug Administration (FDA) has the authority to approve drugs that are used for abortion care.
The resolution emphasizes the importance of ensuring that the FDA is able to fulfill its regulatory responsibilities in a timely and efficient manner, particularly when it comes to approving drugs that are used for abortion care. It also highlights the need for the FDA to base its decisions on scientific evidence and medical expertise, rather than political considerations.
The resolution does not seek to change any existing laws or regulations related to abortion care. Instead, it simply expresses the opinion of the House of Representatives that the FDA should be able to carry out its duties without interference or obstruction. Overall, Bill 118 HRES 309 is a non-binding resolution that serves to reaffirm the belief that the FDA has the authority to approve drugs for abortion care. It is a statement of support for the FDA's regulatory role in ensuring the safety and efficacy of medications used in abortion procedures.
The resolution emphasizes the importance of ensuring that the FDA is able to fulfill its regulatory responsibilities in a timely and efficient manner, particularly when it comes to approving drugs that are used for abortion care. It also highlights the need for the FDA to base its decisions on scientific evidence and medical expertise, rather than political considerations.
The resolution does not seek to change any existing laws or regulations related to abortion care. Instead, it simply expresses the opinion of the House of Representatives that the FDA should be able to carry out its duties without interference or obstruction. Overall, Bill 118 HRES 309 is a non-binding resolution that serves to reaffirm the belief that the FDA has the authority to approve drugs for abortion care. It is a statement of support for the FDA's regulatory role in ensuring the safety and efficacy of medications used in abortion procedures.
Congressional Summary of HRES 309
This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.
Read the Full Bill
Current Status of Bill HRES 309
Bill HRES 309 is currently in the status of Bill Introduced since April 19, 2023. Bill HRES 309 was introduced during Congress 118 and was introduced to the House on April 19, 2023. Bill HRES 309's most recent activity was Referred to the House Committee on Energy and Commerce. as of April 19, 2023
Bipartisan Support of Bill HRES 309
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
96Democrat Cosponsors
96Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HRES 309
Primary Policy Focus
HealthAlternate Title(s) of Bill HRES 309
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Comments
Sponsors and Cosponsors of HRES 309
Latest Bills
RED Tape Act
Bill HR 6398April 17, 2026
FENCES Act
Bill HR 6409April 17, 2026
A bill to amend title 23, United States Code, to withhold Federal highway funding from States that issue driver's licenses, commercial driver's licenses, or personal identification cards to individuals without verifying the legal status of those individuals, and for other purposes.
Bill S 4317April 17, 2026
A resolution designating the week of April 13 through April 19, 2026, as "National Osteopathic Medicine Week".
Bill SRES 674April 17, 2026
A resolution supporting the designation of the week of April 11 through April 17, 2026, as "Black Maternal Health Week", founded by Black Mamas Matter Alliance, Inc., to bring national attention to the maternal and reproductive health crisis in the United States and the importance of reducing maternal mortality and morbidity among Black women and birthing people.
Bill SRES 675April 17, 2026
A resolution recognizing and honoring National Mushroom Day and the contributions of Chester and Berks Counties to the national mushroom industry and to healthy diets.
Bill SRES 676April 17, 2026
A resolution expressing the sense of the Sente that the President should prioritize securing the release of Pastor Jin Mingri, Pastor Gao Quanfu and his wife Pang Yu, Dr. Gulshan Abbas, and Jimmy Lai detained by the People's Republic of China during future engagements with Chinese President Xi Jinping.
Bill SRES 677April 17, 2026
A resolution prohibiting the use of funds for travel by Senators to or from their residence during Government shutdowns.
Bill SRES 678April 17, 2026
A resolution recognizing April 14, 2026, as "World Quantum Day", and commemorating and supporting the goals of World Quantum Day.
Bill SRES 679April 17, 2026
Stop Child Care Fraud Act of 2026
Bill HR 7725April 17, 2026